Coherus Oncology (CHRS) Current Assets (2013 - 2026)
Coherus Oncology (CHRS) posted Current Assets of $206.0 million for Q1 2026, little changed sequentially from $206.7 million in Q4 2025, and down 33.57% YoY from $310.2 million in Q1 2025.
Coherus Oncology (CHRS) Current Assets (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Current Assets for 14 years, with the latest figure at $206.0 million in Q1 2026.
- Quarterly Current Assets fell 33.57% year-over-year to $206.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $206.0 million (down 33.57% YoY) and the FY2025 annual result came in at $206.7 million, down 39.49% from the prior year.
- Current Assets steadied at $206.0 million in Q1 2026 per CHRS's latest filing, from $206.7 million in the prior quarter.
- Over five years, Current Assets peaked at $627.5 million in Q1 2024 and troughed at $206.0 million in Q1 2026.
- A 5-year average of $404.1 million and a median of $385.5 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2024 and 2025: Current Assets soared 98.62% in 2024, then plunged 50.57% in 2025.
- Over 5 years, Current Assets stood at $381.2 million in 2022, then grew by 24.76% to $475.6 million in 2023, then fell by 28.18% to $341.6 million in 2024, then slumped by 39.49% to $206.7 million in 2025, then dropped by 0.32% to $206.0 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $206.0 million, $206.7 million, and $461.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | 133.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 133.79 Mn |
| Mar 31, 2026 | 206.04 Mn |
| Dec 31, 2025 | 206.71 Mn |
| Sep 30, 2025 | 460.96 Mn |
| Jun 30, 2025 | 380.21 Mn |
| Mar 31, 2025 | 310.18 Mn |
| Dec 31, 2024 | 341.58 Mn |
| Sep 30, 2024 | 369.02 Mn |
| Jun 30, 2024 | 557.93 Mn |
| Mar 31, 2024 | 627.48 Mn |
| Dec 31, 2023 | 475.63 Mn |
| Sep 30, 2023 | 444.37 Mn |
| Jun 30, 2023 | 385.48 Mn |
| Mar 31, 2023 | 315.93 Mn |
| Dec 31, 2022 | 381.23 Mn |
| Sep 30, 2022 | 448.28 Mn |
| Jun 30, 2022 | 446.78 Mn |
| Mar 31, 2022 | 512.44 Mn |
| Dec 31, 2021 | 602.32 Mn |
| Sep 30, 2021 | 673.04 Mn |